Access to safe, effective, rapid-acting antidepressants can enhance lives and reduce suicide among patients with treatment-resistant depression or in a crisis.
Ketamine, which can
relieve depression even in treatment-resistant individuals, is one current
potential being researched. Ketamine has been used as an anesthetic for more
than 50 years, although it causes major side effects such as addiction,
hallucinations, and delusions. While preclinical studies have indicated that a
single dosage of ketamine can have long-term mental health benefits, it is only
used as a last option to treat depression.
There are strong
reasons to be careful; in addition to the negative side effects, the exact
mechanism by which ketamine changes brain chemistry is unknown. New medications
might be created to target the positive antidepressant effect of ketamine if
the molecular pathways that ketamine modulates in the brain are uncovered.
Ketamine therapy increased insulin-like growth factor 1 (IGF-1), a recognized
antidepressant brain chemical, according to the study. They didn't know if this
had anything to do with previously found ketamine-related antidepressant
chemicals such as brain-derived neurotrophic factor (BDNF).
Ketamine (10 and 30
mg/kg) substantially elevated extracellular IGF-1 levels in the mPFC of male
C57BL/6J mice for at least 5 hours, according to in vivo microdialysis. In
three distinct behavioral scenarios, infusing an IGF-1 neutralizing antibody
(nAb; 160 ng/side) into the mPFC 15 minutes before or two hours after ketamine
infusion inhibited the antidepressant-like effects of ketamine (forced swim,
female urine sniffing, and novelty-suppressed feeding tests were conducted 1, 3
and 4 days post-ketamine, respectively).
The intra-mPFC
infusions of BDNF (100 ng/side) and IGF-1 (50 ng/side) had ketamine-like
antidepressant-like effects, which were not prevented by co-infused IGF-1 nAb
and BDNF nAb (200 ng/side). In a mouse lipopolysaccharide (LPS)-induced
depression paradigm, an intra-mPFC infusion of IGF-1 nAb 2 hours after ketamine
prevented the antidepressant-like effects of ketamine. Through mechanistic
target of rapamycin complex 1 activation, intra-mPFC IGF-1 infusion caused
antidepressant-like effects in LPS-challenged rats.
These findings imply
that sustained IGF-1 release in the mPFC, irrespective of BDNF, is required for
ketamine's antidepressant-like effects.